Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Low Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07305246
What this trial is testing

Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer

Who this might be right for
Breast Cancer
First Hospital of China Medical University 120
Not applicableLooking for participantsNCT05945732
What this trial is testing

DESTINY Breast Respond HER2-(Ultra)Low Europe

Who this might be right for
Unresectable Breast CancerMetastatic Breast CancerHER2-low Expressing Breast Cancer+1 more
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company 2,295
Testing effectiveness (Phase 2)Study completedNCT00006228
What this trial is testing

Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)WithdrawnNCT06105008
What this trial is testing

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
RemeGen Co., Ltd.
Testing effectiveness (Phase 2)Looking for participantsNCT07276880
What this trial is testing

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer (TNBC)HER2-Negative Breast Carcinoma+1 more
UNC Lineberger Comprehensive Cancer Center 32
Not applicableLooking for participantsNCT06711055
What this trial is testing

Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Shu Wang 285
Large-scale testing (Phase 3)Active Not RecruitingNCT06144944
What this trial is testing

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

Who this might be right for
Breast Cancer InvasiveHormone-receptor-positive Breast CancerHER2 Low Breast Carcinoma+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 160
Early research (Phase 1)Looking for participantsNCT05872295
What this trial is testing

IKS014 in Advanced Solid Tumors That Express HER2

Who this might be right for
Breast CancerGastric CancerGastroesophageal-junction Cancer
Iksuda Therapeutics Ltd. 165
Testing effectiveness (Phase 2)Looking for participantsNCT06340230
What this trial is testing

SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer

Who this might be right for
HR Positive/HER2 Low Breast Cancer
Shengjing Hospital 93
Testing effectiveness (Phase 2)UnknownNCT04742153
What this trial is testing

MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Who this might be right for
Advanced or Metastatic Breast Cancer
Shanghai Miracogen Inc. 66
Testing effectiveness (Phase 2)Study completedNCT01570036
What this trial is testing

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Who this might be right for
Breast Cancer
George E. Peoples 275
Large-scale testing (Phase 3)Looking for participantsNCT04400695
What this trial is testing

RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 366
Testing effectiveness (Phase 2)Looking for participantsNCT07150208
What this trial is testing

T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis

Who this might be right for
Breast Cancer With Brain MetastasisHER2-low Expressing Breast Cancer
Fudan University 140
Testing effectiveness (Phase 2)UnknownNCT05806671
What this trial is testing

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Not applicableNot Yet RecruitingNCT07130344
What this trial is testing

PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer

Who this might be right for
Metastatic Breast CancerHER 2 Low-expressing Breast Cancer
Centre Paul Strauss 262
Post-approval studies (Phase 4)UnknownNCT05861635
What this trial is testing

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Who this might be right for
Breast CancerNeoadjuvant Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 42
Testing effectiveness (Phase 2)UnknownNCT05953168
What this trial is testing

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 69
Large-scale testing (Phase 3)Active Not RecruitingNCT06561607
What this trial is testing

A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 542
Testing effectiveness (Phase 2)Not Yet RecruitingNCT04301375
What this trial is testing

Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)

Who this might be right for
Mammary Cancer
David Garcia Cinca 27
Testing effectiveness (Phase 2)Looking for participantsNCT07037199
What this trial is testing

Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 45
Next Page